MARIETTA, Ga. , Aug. 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (Nasdaq: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received written notification, as expected, from the Nasdaq Stock Market indicating that the Company's failure to
MARIETTA, Ga. , Aug. 15, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today provided additional background and context to certain points, including third party statements, in an article published by The Wall
MARIETTA, Ga. , Aug. 13, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that a Nasdaq Hearings Panel (the "Panel") granted the Company's request for a listing extension.
Partners with Leading Australian Healthcare Products and Biological Supplier MARIETTA, Ga. , Aug. 9, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it received regulatory approval from the
- Publication in Peer-Reviewed Journal Underscores Statistically Significant Difference Seen in Pain and Foot Function Compared to Control Group - Mean Visual Analog Scale (VAS) Score for Pain Was Reduced by 76% at Three Months in Treatment Group Compared with a 45% Reduction in Control Group
Company Will Request Hearing with Nasdaq Hearings Panel MARIETTA, Ga. , July 26, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today provided an update concerning the status of its compliance with the Listing
Board and Management Continue to Take Action to Improve Internal Practices MARIETTA, Ga. , July 18, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that it has appointed Mark P.
- Pete Petit Resigns as Chairman and Chief Executive Officer - Charles Evans Appointed Chairman of the Board - Bill Taylor Resigns as President and Chief Operating Officer - David Coles Appointed Interim Chief Executive Officer - Board and Management Take Decisive Action with Initiatives to Improve
MARIETTA, Ga. , June 7, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that John D. Harris has joined the Company as its Senior Vice President of International, and also provided an update on the
Company to Restate Financial Statements for Fiscal Years 2012 through 2016, and Interim Periods of 2017 Related to Revenue Recognition Appoints Interim Chief Financial Officer Business Performance Remains Strong MARIETTA, Ga. , June 7, 2018 /PRNewswire/ -- MiMedx Group, Inc.
